Business Context and Reporting Period
Trevi Therapeutics, Inc. (TRVI), a Delaware corporation, filed this Form 8-K on May 9, 2019. The report details corporate governance amendments executed in connection with the closing of the Company's initial public offering (IPO).
Key Financial Metrics
This filing is a current report regarding corporate structure and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change reported is the amendment and restatement of the Company's Certificate of Incorporation and Bylaws effective upon the IPO closing. Key structural changes include:
- Capital Structure: Authorized common stock increased to 200,000,000 shares; all references to existing preferred stock were eliminated, and 5,000,000 shares of undesignated preferred stock were authorized.
- Board Composition: Establishment of a classified board of directors with three classes serving staggered three-year terms.
- Director Removal: Directors may now be removed only for cause, requiring an affirmative vote of at least 75% of stockholder votes.
- Stockholder Rights: Elimination of the ability for stockholders to take action by written consent or to call special meetings.
- Legal Forum: Designation of the Court of Chancery of the State of Delaware as the exclusive forum for most corporate claims and federal district courts for Securities Act claims.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future performance, or specific risk factors beyond the legal implications of the new corporate governance provisions. The document focuses strictly on the procedural execution of the IPO-related charter amendments.
Investor Verification Checklist
- Verify the final IPO pricing and total capital raised in the Company's S-1 filing or subsequent press releases, as this 8-K does not disclose financial proceeds.
- Review the full text of the Restated Certificate of Incorporation (Exhibit 3.1) and Amended and Restated Bylaws (Exhibit 3.2) for specific details on director nomination procedures and stockholder proposal rules.
- Confirm the current share count and ownership structure post-IPO to understand the impact of the new 200 million authorized share limit.